Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Macrophage efferocytosis with VEGFC and lymphangiogenesis: rescuing the broken heart
Patricia A. D’Amore, Pilar Alcaide
Patricia A. D’Amore, Pilar Alcaide
Published May 2, 2022
Citation Information: J Clin Invest. 2022;132(9):e158703. https://doi.org/10.1172/JCI158703.
View: Text | PDF
Commentary

Macrophage efferocytosis with VEGFC and lymphangiogenesis: rescuing the broken heart

  • Text
  • PDF
Abstract

Cardiac repair following ischemic injury is indispensable for survival and requires a coordinated cellular response involving the mobilization of immune cells from the secondary lymphoid organs to the site of damage. Efferocytosis, the engulfment of cell debris and dying cells by innate immune cells, along with lymphangiogenesis, the formation of new lymphatic vessels, are emerging as central to the cardiac healing response. In this issue of the JCI, Glinton et al. used state-of-the-art approaches to demonstrate that efferocytosis induced vascular endothelial growth factor C (VEGFC) in myeloid cells and stimulated lymphangiogenesis and cardiac repair. These findings provide impactful mechanistic information that can be leveraged to therapeutically target pathways in cardiac repair and ischemic heart failure.

Authors

Patricia A. D’Amore, Pilar Alcaide

×

Figure 1

Macrophage efferocytosis induces VEGFC release, leading to lymphangiogenesis, and contributes to cardiac repair after ischemia.

Options: View larger image (or click on image) Download as PowerPoint
Macrophage efferocytosis induces VEGFC release, leading to lymphangiogen...
CD36-dependent efferocytosis induces VEGFC release from myeloid cells and activates macrophage expression of VEGFC through as-yet unknown mechanisms. VEGFC functions in an autocrine manner to dampen macrophage proinflammatory cytokine production as well as in a paracrine fashion to induce lymphangiogenesis and modulate the presence of immune cells, such as Tregs and myeloid cells expressing low levels of MHCII, that are necessary to resolve inflammation and promote myocardial repair.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts